Skip to main content

Advertisement

Table 3 Gamma passing rate of CCR-VMAT plans for the C-shaped phantom and prostate cancers. The prostate cancer data are means ±2 standard deviations

From: Quality assurance of non-coplanar, volumetric-modulated arc therapy employing a C-arm linear accelerator, featuring continuous patient couch rotation

Trajectory C-shaped phantom Prostate cancers (n = 5)
3%/3 mm [%] 3%/1 mm [%] 5%/1 mm [%] 3%/3 mm [%] 3%/1 mm [%] 5%/1 mm [%]
1 98.0 91.5 97.5 98.3 ± 1.7 86.5 ± 2.8 95.9 ± 1.4
2 99.1 92.1 98.6 98.2 ± 0.5 84.9 ± 0.5 95.9 ± 2.2
3 99.2 92.0 98.5 98.4 ± 1.9 85.8 ± 1.8 95.8 ± 0.9
4 99.6 96.7 99.6 98.5 ± 0.8 88.2 ± 4.8 96.5 ± 2.8
5 99.0 92.5 98.3 97.8 ± 1.0 86.0 ± 3.8 96.0 ± 2.5
6 98.9 90.2 98.1 97.5 ± 1.6 85.8 ± 3.6 95.9 ± 2.4
7 99.5 95.8 99.2 97.2 ± 2.3 87.1 ± 5.7 95.8 ± 1.8
  1. Abbreviation: CCR-VMAT non-coplanar, volumetric-modulated arc therapy featuring continuous couch rotation